NEONC TECHNOLOGIES INC
Inglewood, CA · Founded 2008 · CIK 0001478689 · Biotech · Public
Intranasal drug delivery platform that bypasses the blood-brain barrier for CNS disease treatment
neonctech.com →- Grants
- $3.0M
- 8 awards
- Sector median: 1
- Raised
- $394K
- 6 Form D · Feb 2022
- 56 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 17 granted · 23 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓200920112013201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $90,500 | |
| Private capital raised | Form D · SEC | $78,500 | |
| Private capital raised | Form D · SEC | $150,000 | |
| Private capital raised | Form D · SEC | $24,750 | |
| Federal grant | Department of Health and Human Services · Phase I · Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors | $300,000 | |
| Private capital raised | Form D · SEC | $20,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO100 | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO100 | $301,450 | |
| Federal grant | Department of Health and Human Services · Phase I · Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO100 | $1,450 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas | $336,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas | $336,000 | |
| Private capital raised | Form D · SEC | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of NEO212, A Novel Oral Drug for the Treatment of Acute Myeloid Leukemia | $399,998 | |
| Federal grant | Department of Health and Human Services · Phase II · Developing a Clinically Relevant Radiosensitizer for Temozolomide-resistant Gliomas | $1,007,612 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1391 | GROVE BIOPHARMA, INC. | — | — |
| 1392 | CYNVEC, LLC | — | $500K |
| 1393 | Infinite Elements, Inc. | — | — |
| 1394 | NEONC TECHNOLOGIES INC | — | $394K |
| 1395 | NOVO HEAL, INC. | — | — |
| 1396 | 3RT INNOVATIONS | — | — |
| 1397 | Granite Bio | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Frank AdellDirector
- Thomas ChenDirector · Executive Officer
- Alan ChiangDirector
- Clovis Da FonsecaDirector
- Clovis FonsecaDirector
- Marc GirouxDirector
- Eytan LambrosoDirector · Executive Officer
- Danny LevinDirector
- Matthew LinDirector
- Eytan LombrosoDirector · Executive Officer
- Floyd LoopDirector
- Clovis Orlando da FonsecaDirector
- Paul ReepExecutive Officer
- Daniel SaksExecutive Officer
- Josh ShacharDirector
- Vicki ShihDirector
- Vincent SimmonExecutive Officer
- James WaltersDirector
- Jim WaltersDirector · Executive Officer
- Patrick WaltersDirector · Executive Officer
Patents
- Pharmaceutical Compositions Comprising Poh Derivativesgranted
- Combination Of Poh And Remdesivir For Treatment Of Cns Infectionsapplication
- Methods Of Permeabilizing The Blood Brain Barriergranted
- Pharmaceutical Compositions Comprising Monoterpenesgranted
- Treatment Of Recurrent Gioblastoma With Perillyl Alcoholapplication
- Methods Of Permeabilizing The Blood Brain Barrierapplication
- Compositions And Methods For Delivering Polynucleotidesapplication
- Pharmaceutical Compositions Comprising Poh Derivatives And Methods Of Useapplication
- Pharmaceutical Compositions Comprising Perillyl Alcohol Derivativesapplication
- Pharmaceutical Compositions Comprising Poh Derivatives And Methods Of Usegranted
- Pharmaceutical Compositions Comprising Poh Derivativesapplication
- Pharmaceutical Compositions Comprising Perillyl Alcohol Derivativesgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.